US equities |
MU $795.41 ▲+0.02% SNDK $1,037.40 ▲+0.00% NVDA $200.13 ▲+0.00% AMD $488.78 ▲+0.00% SKHY $143.07 ▲+0.00% SPCX $135.92 ▲+0.00% INTC $58.27 ▲+0.00% TSLA $385.19 ▲+0.00%
FinancialContent

Calidi Biotherapeutics, Inc. Common Stock (NY:CLDI)

0.7300 UNCHANGED
Delayed Quote Updated: 8:00 PM EST, Nov 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Calidi Biotherapeutics, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Dual-Impact Antibody Combats Multiple Tumor Types in Preclinical Study
Via Investor Brand Network
New Immunotherapy Prolongs Survival of Lung Cancer Patients
Via Investor Brand Network
Expert Shares the Latest Testing and Screening Advances in Breast Cancer Treatment
Via Investor Brand Network
Topics Artificial Intelligence
Eliminating “Immune Fog” Shows Promise in Cancer Interception
Via Investor Brand Network
Blood Samples Could Be Used to Find Cancer-Specific Proteins Needed for Immunotherapy
Via Investor Brand Network
Why Treating Cancer is So Complicated
Via Investor Brand Network
Biomarkers Could Predict Patients’ Response to Bladder Cancer Therapy
Via Investor Brand Network
2 Billion Pounds of Cancer-Causing Chemicals Found Their Way into America in 2020
Via Investor Brand Network
Pancreatic Cancer Exploits Wound-Healing Mechanism to Evade Immune System
Via Investor Brand Network
Systemic Challenges in US Health Care Push Cancer Patients to Fly to China
Via Investor Brand Network
Administering Immunotherapy Prior to Surgery Improves Brain Cancer Treatment Outcomes
Via Investor Brand Network
Boosting Thymus Health Could Improve Treatment Outcomes in Lung Cancer
Via Investor Brand Network
Personalized mRNA Vaccine Prevents Melanoma Recurrence, New Study Finds
Via Investor Brand Network
Mathematical Study Offers Possible Fix to Melanoma Therapy Mystery
Via Investor Brand Network
Little-Known Immune Cells Bolster Anticancer Fight, Study Finds
Via Investor Brand Network
Liquid Biopsy Forecasts Response to Immunotherapy in Lung Cancer Patients
Via Investor Brand Network
Existing Immune Protein May Boost Immunotherapy Against Cancer
Via Investor Brand Network
Researchers Plan to Investigate Role of Autoantibodies in Cancer Risk, Immune Response
Via Investor Brand Network
Dietary Fat Balance Could Influence Immune System Function, Study Finds
Via Investor Brand Network
Study Links Gut Microbial Metabolites to Enhanced Cancer Immunotherapy Sensitivity
Via Investor Brand Network
Understanding Why Treatment Resistance Exists in Many Cancers
Via Investor Brand Network
AI Tool Predicts the Optimal Presurgical Treatments for Breast Cancer
Via Investor Brand Network
Topics Artificial Intelligence
Comprehensive Review Shows Gut Microbiome Influences Immunotherapy Efficacy
Via Investor Brand Network
Currently Approved Drug Could Boost Immunotherapy Against Liver Cancer
Via Investor Brand Network
Why Men Need Sexual Health Help While Undergoing Cancer Treatment
Via Investor Brand Network
FIU Researchers Discover New Way of Extending Immune Cell Lifespan and Effectiveness
Via Investor Brand Network
News headline image
Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on June 9
Via ACCESS Newswire
New Pill Offers Hope Against Pancreatic Cancer
Via Investor Brand Network
New Inhalable Agent Could Improve Treatment Outcomes in Lung Cancer
Via Investor Brand Network
Scientists Inch Closer to Developing a Lung Cancer Blood Test
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 Next >